May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta ...

Vertex is pulling the plug on a treatment for a rare, inherited lung disease after the prospect caused abnormally high levels of liver enzymes in a phase 2 study. It had been testing the drug, VX-814, ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...

Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor ...

SAN DIEGO — For decades, the biotech industry has tried — and repeatedly failed — to develop new and effective painkillers without the addictive potential of opioids. But there’s reason to think that ...